Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
about
Gene aberrations for precision medicine against lung adenocarcinomaTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondCIViC databaseGenomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer ProgressionRAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses.Advancing clinical oncology through genome biology and technology.Oncotator: cancer variant annotation tool.Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patientsDiverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes.A-Raf: A new star of the family of raf kinases.TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.High-throughput Phenotyping of Lung Cancer Somatic MutationsAlterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer.Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.A(nother) RAF mutation in LCH.Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancerClinicopathological examination of dipeptidase 1 expression in colorectal cancer.Differential localization of A-Raf regulates MST2-mediated apoptosis during epithelial differentiationSIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a.Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.Transforming Biomarker Development with Exceptional Responders.Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.Pervasive genetic interactions modulate neurodevelopmental defects of the autism-associated 16p11.2 deletion in Drosophila melanogaster.
P2860
Q26749348-71900A2C-1697-420A-A11C-BA103DC61744Q27026323-5598DEA9-3E76-4A35-AC5C-2997AD9D9BB0Q27612411-C44BB7B0-8145-4386-B150-07F6B356CD59Q27853189-5BBC24B1-A07F-4EBB-8B4F-29C23946E831Q28552533-0F8E720C-BC66-4DD9-BB15-A8DF25AE5B1EQ33705675-D4D48411-5B40-45E0-A63A-13BFD8F8DE87Q33767521-9617FE54-3529-4A65-BC73-FBCC60A3461BQ34803010-D7B5AA56-188F-48CE-8668-927EEE74B28FQ35565104-34357F4B-0222-4964-A052-B0008C65D1DBQ35746639-B01DA43D-FDA5-44CD-9D83-53EB7E04BCBBQ35920997-A3EBD0EF-D233-4B11-8229-C9768ECAC189Q36023919-A903DCD9-55A6-4AE8-9484-BC3C4811CBA6Q36070099-9992863F-1BF7-4CB6-9038-58D82CC8BE0FQ36140832-B4BDF5FF-D9F4-4C18-ADD0-70707A1DBEA4Q36544077-4CC6885F-4310-4D47-AE10-CEC68A21A0A0Q36553791-D8E4F3EE-9E82-4D2D-941E-C3E9DC2B2B98Q36586426-07D51AC5-A548-49F2-A401-619BBA788CC2Q37295744-BAB376DF-987F-4A25-BD73-0DA2566ABE61Q37529618-3C54584C-07D6-4EE4-9703-F61A0D9DC43FQ38618036-0321F77C-1FA1-40F3-826B-D1DB0976EB6DQ38748274-9DE7AA8F-B726-49FE-B441-69FEADC7BC10Q38754469-5FE1B8E1-4EC4-44E7-A747-B82824D0B9CAQ38825099-CA7C9EA8-57AB-47E5-AFCC-449B9C2ADF3BQ38826254-E9C73746-2510-415D-8EEB-195F67AA3115Q38870624-F4526964-D48B-40C4-A403-5D6FF143AE82Q38881066-B26FA30C-1BC4-4EFE-9DE2-C946BA59DD76Q38910529-AE6CE9E1-80C6-4624-81A3-48A6893CFFEEQ39675111-939BA9EE-ECEF-4743-84E7-8002430F3F68Q41091941-595FD43F-533F-4ADE-A1B9-D29D91D459ECQ42087584-E7D5FDC5-FC07-48CD-A1CD-38CA3C7DE2B3Q42117499-482DD385-6F6D-4BA0-812D-D7D2AF1FCB59Q42416308-951B9E96-F721-4037-9CF5-D7118E6C3EA5Q47144786-B89DA984-9858-4547-AB33-05EEBA339771Q47151526-B8544290-2714-4352-95B8-D20D43B9DABBQ50138587-F0962239-237B-4F5C-87E7-261346E4F26CQ50643518-5CEB57C6-E92D-4C1F-9DD3-9792C619C4DFQ51605334-717DDFE5-6753-4957-89F4-5C8C6C38D42EQ55393701-48EBADAD-A59E-46DA-85D5-91BFB6C84BE9
P2860
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@ast
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@en
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
@nl
type
label
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@ast
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@en
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
@nl
altLabel
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@en
prefLabel
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@ast
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@en
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
@nl
P2093
P2860
P50
P3181
P356
P1476
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
@en
P2093
Bethany Kaplan
David P Carbone
Joan Schiller
Joseph Amann
Leora Horn
Luiz Araujo
Miguel A Villalona-Calero
P2860
P304
P3181
P356
10.1172/JCI72763
P407
P577
2014-04-01T00:00:00Z